Computer generated 3D model, showing a cross-section of the green RNP spirals, blue hemagglutinin, red neuraminidase, and purple m2 ion channels that constitute the structure of the Influenza A Virus ...

ATLANTA—A new universal flu vaccine constructed with key parts of the influenza virus offers broad cross protection against different strains and subtypes of influenza A viruses in young and aged ...

A new universal flu vaccine constructed with key parts of the influenza virus offers broad cross protection against different strains and subtypes of influenza A viruses in young and aged populations, ...

Vaccines work by exposing our immune system to viral proteins. Our immune system then recognizes these proteins as foreign molecules —antigens— and springs into action, neutralizing the threat. As ...

CRANBURY, N.J.-(BUSINESS WIRE)-Aug 21, 2008 - VaxInnate Corporation announced today that its M2e universal influenza vaccine candidate was safe and immunogenic in its first Phase I clinical trial, ...

With the morbidity and mortality rates for this year’s influenza season beginning to mount there is some welcome news from investigators at the Institute for Biomedical Sciences at Georgia State ...

Cranbury, NJ, September 25, 2007 – VaxInnate Corporation announced today that it has commenced its first Phase 1 clinical trial, testing its M2e universal influenza vaccine. The universal vaccine is ...

New York, July 4 (IANS) A new universal flu vaccine, constructed with key parts of the influenza virus, offers broad cross protection against different strains and subtypes of influenza A viruses in ...

Some commercial influenza vaccines contain adjuvants, components added to increase immune response and enhance the vaccines’ effectiveness. Although these adjuvants generally cause only mild side ...

Influenza is a global health concern. Licensed influenza vaccines induce strain-specific virus-neutralizing antibodies but hamper the induction of possibly cross-protective T-cell responses upon ...

In a recent study published in the Journal of Virology, researchers developed a recombinant bivalent vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and influenza viruses.